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Abstract
Apelin, a novel peptide originally isolated from bovine stomach tissue extracts, is widely but
selectively distributed throughout the nervous system. Vasopressin and oxytocin are synthesised in
the magnocellular neurons of the hypothalamic supraoptic (SON) and paraventricular nuclei
(PVN), which are apelin-rich regions in the central nervous system. We made extracellular
electrophysiological recordings from the transpharyngeally exposed SON of urethane-
anaesthetised rats to assess the role of apelin in the control of the firing activity of identified
magnocellular vasopressin and oxytocin neurons in vivo. Apelin-13 administration onto SON
neurons via microdialysis revealed cell-specific responses; apelin-13 increased the firing rates of
vasopressin cells, but had no effect on the firing rate of oxytocin neurons. A direct excitatory
effect of apelin-13 on vasopressin cell activity is also supported by our in vitro studies showing
depolarisation of membrane potential and increase in action potential firing. To assess the effects
of apelin-13 on somato/dendritic peptide release we used in vitro release studies from SON
explants in combination with highly sensitive and specific radioimmunoassays. Apelin-13
decrease basal (by 78%, p<0.05, n=6) and potassium-stimulated (by 57%, p<0.05, n=6)
vasopressin release but had no effect on somato/dendritic oxytocin release.
Taken together, our data suggest a local autocrine feedback action of apelin on magnocellular
vasopressin neurons. Furthermore, these data show a marked dissociation between axonal and
dendritic vasopressin release with a decrease in somato/dendritic release but an increase in
electrical activity at the cell bodies, indicating that release from these two compartments can be
regulated wholly independently.
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Introduction
Immunohistochemical and in situ hybridisation studies have shown that apelin, a peptide
originally isolated from bovine stomach tissue extracts (1), is widely distributed throughout
the body, as well the central nervous system (2-8). Apelin is derived from a 77-amino acid
precursor, pre-pro-apelin, which is processed to several different forms in different tissues
(4;7). Those reported to have the highest in vitro activity on the G-protein-coupled, seven-
transmembrane domain apelin receptor (APJ) are apelin-13 and apelin-17 (3;9). The highly
conserved structure of apelin and its receptor between species has prompted suggestions of
important physiological functions for apelin and, so far, roles in pressure/volume
homeostasis, modulating pituitary hormone release, food and water intake, and stress and
immune system activation have been described (reviewed by (10-17).
Like APJ, apelin is found in a variety of brain areas including hippocampus, cerebellum,
striatum and hypothalamus (4-6;8;11;18;19). Some of the most apelin-rich regions in the
brain, with a dense network of apelin-immunoreactive nerve cell bodies, dendrites and
axons, are the vasopressin and oxytocin synthesising magnocellular neurons of the
supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus (9;20). The
neuropeptides are released from axon terminals in the neural lobe of the pituitary and from
somata and dendrites within the hypothalamus. Vasopressin and oxytocin secretion from the
pituitary into the general circulation plays a considerable role in the physiological regulation
of fluid homeostasis and reproduction. Oxytocin and vasopressin released from dendrites act
as retrograde signals that modulate synaptic transmission, electrical activity and, in some
cases, morphology of the cell of origin (reviewed in (21;22)).
Initially a subpopulation of apelin-immunoreactive magnocellular neurons were shown to be
oxytocinergic, as indicated by their signal for neurophysin I (9). However, a recent paper has
shown that almost all apelin-immunoreactive cells are immunopositive for vasopressin;
although the apelin-immunoreactive cells represented only a small subset of vasopressin
neurons. Although both were found in the cytoplasm, the apelin and vasopressin signals
were not co-localised within the neurons. Moreover, a 48 hour dehydration stimulus applied
in vivo depleted the somato-dendritic vasopressin signal while resulting in an increased
apelin signal in both the number of apelin positive cells as well as labelling density,
suggesting that the two peptides might be stored in, and therefore differentially released
from, two distinct vesicular pools within the same cells (23). In addition to apelin, APJ
mRNA is expressed in magnocellular neurons (3;18), suggesting a local role of apelin/APJ
in regulating vasopressin neurons.
However, contrasting effects of apelin in regulating vasopressin release and drinking
behaviour have been reported. Intracereboventricular (i.c.v.) injection of apelin-17 decreased
the electrical activity of vasopressin cells in lactating animals (24). I.c.v. injection of
apelin-13 or apelin-17 inhibited basal and dehydration-induced release of vasopressin and
water intake in mice and rats (18), suggesting an inhibitory role of apelin in the regulation of
vasopressin release. Two other studies observed regulatory actions of apelin on fluid
homeostasis; apelin-13 administered i.c.v. dose-dependently increased water intake (5;25) or
had no effect on water intake in sated or water-deprived rats (26).
Therefore, the aim of this study was to determine the direct effects of apelin-13 on the
electrical activity and somato/dendritic peptide release of vasopressin and oxytocin neurons.
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Material and Methods
Animals
Sprague-Dawley control (Bantin & Kingman, UK) or Wistar rats expressing a vasopressin-
enhanced green fluorescent protein (vasopressin-eGFP (27-29)) were used in accordance
with the UK Animals (Scientific Procedures) Act, 1996. Experiments conducted in Japan
were in accordance with guidelines on the use and care of laboratory animals as set out by
the Physiological Society of Japan and was approved by the Ethics Committee of Animal
Care and Experiments of the University of Occupational and Environmental Health,
Kitakyushu, Japan. Only the minimum number of rats necessary to produce reliable
scientific data was used. All rats were housed under controlled conditions (12 h light: 12 h
dark, 21 C) with free access to food and water.
Immunocytochemistry
Adult (250-300 g) random cycling female rats were deeply anaesthetised (Sagatal, 0.6ml,
intraperitoneal) then perfused through the ascending aorta first with heparin (5000 U/ml;
300 ml) in 0.9% saline solution followed by 300 ml of a 4% paraformaldehyde in 0.1 M
phosphate buffer (PB, pH 7.4). The brain and pituitary were carefully removed and
immersed overnight in a solution of 0.2% paraformaldehyde and 15% sucrose in 0.1 M PB
at 4 C. The tissue was then placed in a solution of 30% sucrose in 0.1 M PB and left at 4 C
until the tissue had sunk (usually 48 h). Tissue sections (40 μm) were cut with a freezing
microtome and rinsed in 0.1 M PB. Sections were first incubated for 30 min at room
temperature in a blocking buffer consisting of 1% BSA + 0.2% Triton X-100 in 0.1 M PB.
Sections were incubated for 60 min at room temperature then 48 h at 4 C with primary
antibodies against the apelin receptor (APJ, rabbit polyclonal, diluted 1:50, Santa Cruz, UK,
(30)), plus glial fibrillary acidic protein (GFAP, mouse monoclonal, IMGENEX; diluted
1:200) or oxytocin (neurophysin-oxytocin PS38, mouse monoclonal, diluted 1:5000) or
vasopressin (neurophysin-vasopressin PS41 mouse monoclonal; diluted 1:5000). The
vasopressin and oxytocin antibodies were a kind gift of Professor H. Gainer. After rinsing in
0.1 M PB, sections were incubated for 60 min at room temperature in secondary antibodies
against rabbit IgG conjugated with Alexa 488 and mouse IgG Alexa 568 (each diluted
1:1000, Molecular Probes, Eugene, OR, USA). Both primary and secondary antibodies were
diluted in blocking buffer. The sections were mounted in a Mowiol mounting medium
(Calbiochem, San Diego, CA, USA), supplemented with 2.5% DABCO (Sigma) and
fluorescence immunoreactivity observed with a Leica TCS-NT microscope equipped with
an Argon/Krypton laser. Emissions from each fluorescent secondary antibody were acquired
consecutively to ensure no cross-talk from one channel to another. No fluorescent labelling
was detected when primary antibodies were omitted. Images were acquired and viewed
using Leica Confocal Software (Leica Microsystems, Heidelberg, Germany).
In vivo electrophysiology
Female Sprague-Dawley rats were anaesthetised with intraperitoneal injection of urethane
(1.25 g/kg); a femoral vein and the trachea were cannulated and the pituitary stalk and right
SON were exposed transpharyngeally as described previously (31). In some animals an
additional i.c.v. cannulae was implanted. A home-made U-shaped dialysis probe (molecular
cut-off 6000Da, Spectra/Por RC Hollow Fibers®, Spectrum Med. Inc.) was bent to position
the loop of the membrane flat onto the exposed ventral glial lamina of the SON after
removal of the meninges (32). A glass micropipette (filled with 0.15 M NaCl, 20-40 MΩ)
was introduced into the centre of the loop of the dialysis probe to record the extracellular
activity of single neurons in the SON. A bipolar stimulating electrode (SNEX-200X, Clarke
Clarke Electromedical Instruments, Reading, UK) was placed on the pituitary stalk and set
to deliver single matched biphasic pulses (1 ms, <1 mA peak to peak) for antidromic
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identification of SON neurons. Oxytocin neurons were distinguished from vasopressin
neurons by their firing pattern and by their opposite response to i.v. cholecystokinin (CCK,
20 μg/kg, cholecystokinin-(26-33)-sulphated, Bachem Ltd., Saffron Walden, Essex, UK),
i.e. transient excitation of oxytocin neurons and no effect or short-term inhibition of
vasopressin neurons (33). Artificial cerebrospinal fluid (aCSF, pH 7.2, composition in mM:
NaCl 138, KCl 3.36, NaHCO3 9.52, Na2HPO4 0.49, urea 2.16, CaCl2 1.26, MgCl2 1.18)
was dialysed at 3 μl/min throughout the experiment. During recording, dialysis fluid was
changed to aCSF containing apelin-13 fragment (1 μg/μl) for 30 min. Drugs administered
by microdialysis in this way penetrate only a short distance into the brain - the
concentrations achieved 0.5-1 mm below the surface of the brain are about 3 to 4 orders of
magnitude below the dialysate concentration over this duration of infusion (32). In some
animals apelin-13 was given i.c.v. at a dose of 0.1 μg/2 μl. At the end of each experiment
the rats were killed by overdose of pentobarbitone anaesthetic (60 mg/kg, i.v.). The firing
rates of cells were recorded using Spike2 software (Cambridge Electronic Design,
Cambridge, UK) and interfaced to a personal computer. The mean firing rate (spikes/s) and
the activity quotient (proportion of time in which a cell is active) were analysed for 10 min
intervals before, during and after drug treatment.
In vitro electrophysiology
Recordings of apelin-induced currents were made in magnocellular neurons from isolated
neuron and brain slice preparations. Neurons were isolated as previously described (34) with
the following minor modifications. In brief, 600 μm thick coronal hypothalamic slices,
including the SON, were prepared in constantly O2 bubbled ice-cold Locke solution (in mM:
NaCl 140, KCl 5, Hepes 10, Glucose 10, KH2PO4 1.2, MgSO4 1.2 and CaCl2 1.8, adjusted
to pH 7.4 with NaOH and osmolarity 295-300 mOsm) from brains removed from 60-80 g
vasopressin-eGFP or wild type rats. Punches (1.8mm in diameter) were made of the SON,
transferred to a conical container and incubated in O2-bubbled Locke solution containing
DNAse (0.5 mg/ml) and Protease X (1 mg/ml) for 20 min at room temperature. This solution
was replaced with one containing DNAse (0.5 mg/ml) and Protease XIV (1 mg/ml) and
incubated for a further 20 min at room temperature. The tissue punches were washed with
normal Locke buffer for at least 2 h before gentle manual dispersal of cells with fire-
polished Pasteur pipettes. The use of tissue punches was observed to result in a far greater
number of healthy cells with less cellular debris and non-magnocellular neurons than using
SONs dissected from the brain. The cell suspensions were plated onto glass-bottom culture
dishes (HBSt or GWSt-3522 series; 22 mm diameter, 0.17 mm thickness; WillCo Wells BV,
Amsterdam, The Netherlands) with custom-made polycarbonate inserts to allow rapid
perfusion. The eGFP-expressing isolated magnocellular neurons were identified by their
green fluorescence and cells were patched under visible light at room temperature.
Recordings were also made in 250μm hypothalamic slices containing SONs. The slices
were prepared as above, without enzyme treatment, from wild-type Sprague Dawley rats as
well as vasopressin-eGFP rats. Slices were allowed to rest for at least 60min in oxygenated
Locke solution at room temperature before being transferred to a heated perfusion chamber
mounted on a Zeiss Axioskop epifluorescence microscope. Again, eGFP cells were
identified using their green fluorescence and SON magnocellular neuron cell bodies were
patched using infrared-DIC optics. Images were acquired using a Hamamatsu Orca-ER
camera controlled by Simple PCI software (Digipixel). Patch electrodes were fabricated
from borosilicate capillary tubing of 1.5 μm diameter (Garner Glass Co., Claremont, CA).
The pipette solution contained (in mM) 134 potassium methanesulfonate, 5 KCl, 0.1 K-
EGTA, 5 Na-HEPES, 3 Mg-ATP, and 0.4 Na-GTP (pH 7.4) (4–6 MΩ). Membrane
potentials were recorded in current-clamp mode, with a patch-clamp amplifier (Axopatch
200B; Axon Instruments, Union City, CA). Recorded signals were low-pass-filtered at 1–2
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kHz, digitized at 2–5 kHz with an A/D converter (Digidata 1322A; Axon Instruments), and
analyzed with the pClamp software (Axon Instruments).
Calcium imaging from isolated magnocellular neurons
Magnocellular neurons from wild type rats were enzymatically treated as described above.
The tissue pieces were then rinsed with normal Locke solution and maintained in
oxygenated normal Locke solution at room temperature until dissociated mechanically by
gentle titration. The resulting cell suspension was gently mixed with a solution containing
Fura-2/AM and pluoronic acid in normal Locke buffer to give a final concentration of 1 μM
and 0.01% respectively. The cell suspension was then plated onto clean poly-L-lysine
treated coverslips (22 mm diameter No. 0: Merk) which formed the base of heated perfusion
chambers for [Ca2+]i measurements. After 30 min at room temperature, the coverslips were
gently rinsed to remove unattached cells and unincorporated dye. After a further 30 min
incubation at room temperature to allow de-esterification of the Fura-2/AM, perfusion
chambers were placed on the temperature-controlled stage of an inverted microscope (Nikon
Diaphot TMD) and cells were perfused with oxygenated normal Locke solution or test
solutions as described below at 1 ml/min at 35 C. Cells were viewed with a 40x CF
fluorescence objective (numerical aperture 1.3), and putative magnocellular neurons were
chosen on the basis of size (soma diameter of ~15 μm) and morphology. The Fura-2 was
excited at 340 and 380 nm and emission (520 nm) detected and displayed (ImageMaster Pro
software; Photon Technology International, New Jersey). Images were collected at 3 Hz,
alternating between the two excitation wavelengths. Data were collected from defined
regions of interest within the neurons. Fluorescence values were corrected for background
and dark current and [Ca2+]i was calculated from the ratio between 340 and 380 nm
recordings using a standard curve derived from a Fura-2 Imaging Calibration Kit (Molecular
Probes).
In vitro release experiments
For the in vitro release experiments female Sprague-Dawley rats (100-150 g) were killed by
decapitation and the neurohypophysis, devoid of the pars intermedia, and both SON, were
quickly removed and placed in normal Locke solution as previously described (35). Release
was measured from either individual neurohypophyses, or from four SONs kept in chambers
containing normal Locke media at 37 C. This media was removed and replaced every 5 min
for 30-45 min before collecting any samples, to achieve stable basal levels. Following this
equilibration period, the media samples were retained and stored at -20 C. At time periods
described below, the normal Locke solution was replaced with either a high potassium (K+;
in mM 50 KCl, NaCl 90, Hepes 10, Glucose 10, KH2PO4 1.2, MgSO4 1.2 and CaCl2 1.8,
adjusted to pH 7.4 with NaOH and osmolarity 295-300 mOsm) solution, apelin-13 (50 nM),
or a combination of apelin-13 and high K+. The evoked vasopressin and oxytocin release
during each period was calculated by subtracting the release under basal conditions (five
times the mean of the three samples before the stimulus was applied) from that observed
during, and directly after, the stimulus (a total of five fractions).
Radioimmunoassay
Vasopressin and oxytocin released from the explants was assayed as described before
(oxytocin: (34); vasopressin: (36)), with antibodies kindly supplied by Dr. R. J. Bicknell,
(Babraham Institute, Cambridge, UK). The final antibody dilution for the vasopressin and
oxytocin antibodies was 1:140000 and 1:30000 respectively. The oxytocin and vasopressin
radioimmunoassays had sensitivities of 0.5 pg and 1.0 pg, respectively. The inter- and intra-
assay coefficients of variation were 5-7 %.
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Drugs and Reagents
Apelin-13 was bought from Peptide Institute Inc. (Osaka, Japan) and Phoenix
Pharmaceuticals (CA, U.S.A.). Apelin-13(F13A) was also obtained from Phoenix
Pharmaceuticals. All other reagents were purchased from Sigma unless otherwise stated.
Statistical analysis
Statistical analyses were performed using SigmaStat® software package (SigmaStat
software, Systat Software Inc., Richmond, CA, USA). Data were analysed by t-tests (paired
or unpaired as appropriate after passed normality tests) or, when appropriate, by ANOVA
followed by Student-Newman-Keuls post-hoc tests. All values are expressed as mean ±
S.E.M., and differences were considered significant at P ≤ 0.05.
Results
APJ receptor distribution in the SON and pituitary
Hypothalamic and pituitary sections were double-labelled with immunofluorescence using
antibodies against vasopressin, oxytocin or glial fibrillary acidic protein (VP, OT and GFAP
respectively, red) and the apelin receptor (APJ, green). Confocal images showed APJ
immunoreactivity in the somata, dendrites, axon fibres and axon terminals of magnocellular
vasopressin and oxytocin neurons (Fig 1A-D). APJ immunoreactivity was also seen in the
ventral glial lamina (Fig. 1E) and in some cells of the anterior pituitary (not shown).
In vivo electrophysiology
Experiments to determine the direct effects of apelin-13 on magnocellular neurons were
carried out on 8 identified vasopressin and 7 oxytocin neurons. Microdialysis administration
of apelin-13 onto the supraoptic nucleus (one neuron/rat) excited all vasopressin neurons;
characterised by their frequency (spikes/s) and activity quotient (calculated for the 5 min
periods before and during apelin treatment). All continuously active cells were identified by
their response to i.v. CCK (33) showing an increase in the firing rate in oxytocin (to 173% ±
16.7% of control) and a decrease in the firing rate in vasopressin cells (to 76.2% ±9.17% of
control, p<0.01).
Four of the vasopressin cells were continuously active (5.54 ± 1.29 spikes/s) and four
showed phasic firing patterns (activity quotient: 0.68 ± 0.10; intraburst firing rate 7.0 ± 0.63
spikes/s). The activity of the continuous cells rose to 7.0 ± 1.15 spikes/s (p<0.05, Fig 2B)
after administration of apelin-13. The activity quotient in the phasic cells increased to 0.87 ±
0.07 (p<0.05, Fig 2C) and the intraburst firing rate increased to 7.93 ± 0.96 spike/s (p<0.05)
within 20-30 min of apelin-13 administration. In contrast, retrodialysis of apelin-13 tended
to decrease the electrical activity of oxytocin neurons which, however, did not reach
statistical significance (4.47 ± 1.16 spikes/s before and 3.13 ± 1.1 spikes/s after apelin, Fig
2D, E).
Since the effects of apelin-13 on vasopressin cells observed here were in contrast with a
previous report using i.c.v. injection of apelin-17 in lactating rats (24), in nine experiments
we administered apelin-13 i.c.v. and recorded from five continuously active and four phasic
active vasopressin cells. There was no change in the activity of the continuous active
vasopressin cells within the time of recording (Fig 3A, C) but a significant increase in the
activity quotient of the phasic cells (from 0.52 ± 0.06 to max 0.86 ± 0.09, p<0.05, Fig 3B,
D). The intraburst firing rate did not change significantly in the phasic cells (from 9.29 ±
1.45 spikes/s to 9.86 ± 1.91 spikes/s) within 30 min after apelin-13 administration.
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Effect of apelin on membrane potential and currents in isolated neurons and hypothalamic
brain slices
The effects of apelin-13 on membrane potentials and ionic currents of SON neurons were
studied by the whole cell patch-clamp technique. Initially studies were made using
dissociated SON neurons from heterozygous GFP-vasopressin rats (27). In voltage-clamp
mode, cells were held at -40 mV and stepped from -120 to -40 mV in 10 mV increments,
each step over 200 ms. All GFP-positive neurons were observed to have a linear current-
voltage relationship ie. no hyperpolarisation-induced inward rectification at potentials more
negative than -90 mV or a sustained outward rectification at potentials more positive than
-70 mV (data not shown). This was consistent with previous studies identifying SON
magnocellular neurons with a linear current-voltage relationship to express vasopressin by
post-hoc immunocytochemistry (37). Nearly all of the GFP negative cells showed an
outward rectification, indicating them to be oxytocin cells. Thus, later studies using non-
GFP vasopressin rats utilised the presence or absence of an outward rectification in response
to this protocol to identify oxytocin and vasopressin neurons respectively.
In voltage-clamp mode, all isolated vasopressin neurons (n=10, a typical example is shown
in Fig. 4A) showed inward currents, on average 55 ± 16.5 pA in amplitude in response to
apelin-13 (50 nM, 3 min), when cells were clamped at -70 mV. The response to apelin-13
was rapid, lasted at least the duration of time that apelin-13 was applied, lasting on average
5.5±1.5 min and was readily reversed upon washing out (Fig. 4A). The identity of the
channel(s) carrying the apelin-evoked inward current was investigated using ramp voltage
protocols, stepping from -70 mV to -100 mV, and then ramping up to -20 mV over 4 s.
These were applied three times before and during apelin-13 treatment. The currents used to
calculate the reversal potential were those collected during the maximum evoked current.
The reversal potential of the apelin-induced current was -32 ± 2 (n=5, Fig. 4B). The apelin-
induced current was also completely blocked by the cation channel blocker gadolinium
(Gd3+, 0.1 mM, n=5, Fig. 4C). The peptide apelin-13(F13A) has been described as an APJ-
specific antagonist from its effects in vivo in blocking the hypotensive action of apelin-13
(39). In our in vitro experiments, apelin-13(F13A) (0.1 mM) applied before (10 min) and
during exposure to apelin-13 blocked the apelin-induced inward current, indicating it was
also effective in vitro (n=5, Fig. 5B).
Apelin-13 (50 nM, 3 min) stimulated a small but reproducible increase in [Ca2+]i in 12 out
of 12 vasopressin neurons (Fig. 4D). The identity of the isolated vasopressin neurons was
established by their response to vasopressin (Fig. 4D) as oxytocin neurons do not respond to
vasopressin with an increase in [Ca2+]i (38).This increased [Ca2+]i was absent when
extracellular calcium was removed in 5 of 5 vasopressin neurons (Fig. 4F). As the inward
current was evoked at potentials more negative than -32 mV, it is likely that the apelin-
induced calcium influx occurs via the non-specific cation channel rather than a voltage
operated calcium channel. We also observed apelin-induced increases in [Ca2+]i in oxytocin
neurons (data not shown) but did not pursue this further.
The effects of apelin-13 on membrane potential and action potential firing were examined
using brain slices, as vasopressin neurons in this preparation show patterns of spontaneous
action potentials similar to those recorded in vivo. Cells were identified as vasopressin
neurons either from a fluorescence signal or using the voltage-clamp protocol described
above. Results from wild-type and vasopressin-eGFP rats and both genders were not
different and have been pooled. In current-clamp mode, apelin-13 (50 nM) had a modest
effect, depolarising the membrane potential on average by 5.6±1 mV from an average
resting membrane potential of -58.5±8.5 mV (n=10, Fig 5A). In both non-phasic and
phasically firing neurons, apelin-13 increased the action potential firing rate (Fig 5C). In
general, vasopressin cells did not return to pre-apelin membrane potential and firing rates
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until at least 10 min after perfusion of the drug was stopped. Nevertheless, cells were able to
re-respond to a second apelin-13 exposure. Treatment of hypothalamic brain slices by bath
perfusion with apelin-13(F13A) (0.1 mM, 15 min) was without any significant effect on
spontaneous action potential firing rate or membrane potential of vasopressin neurons (n=10
neurons, Fig. 5B, C).
In contrast to the vasopressin neurons, all isolated neurons or cells in the hypothalamic brain
slices identified as oxytocin neurons showed no increase in inward current upon exposure to
apelin-13 (0.05 or 0.1 mM) or change in membrane potential or action potential firing rate.
In vitro release experiments
To test whether the effects of apelin-13 are mediated through somato/dendritic or axon
terminal release of vasopressin or oxytocin, we studied hormone release from isolated neural
lobes and SON in vitro. The responses of vasopressin and oxytocin release from both
compartments were similar after repeated stimulation with 50 mM K+ solution (Fig. 6).
Apelin-13 (50 nM) given for 20 min between the two potassium stimuli significantly
decreased basal vasopressin (by 78%, p<0.05, n=6), but not oxytocin release, from the SON
preparations. Release of both hormones from the neural lobe was not affected by the apelin
treatment (Fig 6). Apelin-13 (50 nM) also significantly inhibited 50 mM K+-evoked
vasopressin release from the SON explants (by 57%, p<0.05, n=6, Fig 7).
In both the SON and neural lobe preparations apelin-13 often appeared to stimulate
vasopressin release within the first five min. However, this small increase was not
statistically significant. The K+-evoked release of oxytocin from the SON and vasopressin
and oxytocin from the neural lobes was also not affected by apelin-13 (Fig. 7).
Discussion
The present study demonstrated that both oxytocin and vasopressin neurons are
immunoreactive for apelin receptors. Apelin-13 administration to isolated vasopressin and
putative oxytocin neurons provoked an increased [Ca2+]i in both cell types. However,
apelin-13 increased the electrical activity in vivo and in vitro of vasopressin cells only.
Finally, apelin-13 decreased basal and potassium stimulated somato-dendritic vasopressin
release without affecting oxytocin release.
These data again show a marked dissociation between axonal and dendritic vasopressin
release with a decrease in somato/dendritic release but an increase in electrical activity at the
cell bodies, which we anticipate would result in increased terminal secretion. However, we
did not measure the contemporaneous vasopressin release from the neural lobes after
apelin-13 was applied in vivo to the somata and dendrites via the microdialysis probe. This
is because the apelin-13 was applied to only one of the four nuclei that project to the neural
lobe and a change in the firing rate of vasopressin neurons in one treated nucleus may not
necessarily be reflected in a change in output at the neural lobe.
Generally, increased action potential firing is accompanied by increased secretion. Here we
show that apelin-13 increases the electrical activity of vasopressin neurons, while decreasing
somato/dendritic release. However, this is not the first observation that a change in action
potential firing rate does not alter peptide release from magnocellular neuron somata and
dendrites (35).
That release from these two compartments can be regulated wholly independently has been
previously shown (35;40). For example, oxytocin cells express MC4 receptors, through
which α–MSH acts and MC4 agonists trigger intracellular calcium release in oxytocin cells,
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evoke dendritic release of oxytocin, and induce expression of the immediate-early gene c-
fos. However, α-MSH inhibits the electrical activity of oxytocin neurones and so reduces
the secretion of oxytocin into the blood (40).
APJ was distributed throughout magnocellular vasopressin neurons with intensive labelling
of cell bodies, dendrites and axon terminals. APJ immunoreactivity was also seen on
oxytocin cells and cells of the anterior pituitary. Labelling of vasopressin neurons is in
accordance with previous in situ hybridisation studies showing APJ mRNA expression in
vasopressin cells which is unregulated during osmotic stimuli (41). Using in situ
hybridisation combined with immunohistochemistry, high expression of apelin mRNA in
corticotrophs of the anterior pituitary has been shown, suggesting a local interaction between
apelin and the release of adrenocorticotropin (42). The physiological significance of APJ
expression on oxytocin neurons is currently unknown; in our experiments, apelin
administration had no effect on the electrical activity of oxytocin neurones activity in vivo
and in vitro or somato/dendritic oxytocin release at doses that affected vasopressin cell
activity and vasopressin release. Likewise, despite a strong immunocytochemical APJ
signal, application of apelin-13 to neural lobe preparations had no effect on vasopressin
release from axon terminals in vitro.
There was also intensive APJ staining in the ventral glia lamina. Co-localisation of APJ with
the glial cell marker GFAP has been reported previously (8;43). However, in the former
paper, glial cell expression of APJ was thought to be in oligodendrocytes with limited
expression in astrocytes where oligodendrocytes and astrocytes were identified by staining
against galactosylceramide and GFAP respectively. Choe and colleagues (43) reported that,
despite the presence of APJ immunoreactivity, astrocytes stimulated with apelin did not
show an increase in [Ca2+]i. The functional significance of APJ expression on astrocytes
remains unknown.
The literature regarding the effects of apelin in regulating vasopressin release and drinking
behaviour is controversial. I.c.v. injection of apelin-13 and apelin-17 inhibited basal and
dehydration-induced release of vasopressin and water intake in mice and rats (18),
suggesting an inhibitory role of apelin in the regulation of vasopressin release. However, in
other studies apelin-13 administered i.c.v. dose-dependently increased water intake in rats
(5;25) or had no effect (26).
In our in vivo preparation, apelin-13 was applied directly onto supraoptic neurons by
microdialysis administration (32), resulting in an increase in the activity quotient (phasic
cells) and mean spike activity (continuous active cells) of all vasopressin cells tested. This
finding is in direct contrast to the results on lactating animals recently published by others
(24). I.c.v injection of the apelin agonist K17F induced a gradual and sustained inhibition of
phasic vasopressin cells for up to 60 min after injection (24). In our study, in virgin female
rats, we did not find any changes in the activity of continuous active vasopressin or oxytocin
cells within 15-30 min after i.c.v. apelin-13 injection, but again found a significant increase
in the activity quotient of phasic active cells. These differences may be due to the
physiological conditions of the animals. In the lactating rat model, vasopressin neurons are
hyperactive (44) in order to preserve body water content and to optimise milk production.
Alternatively, apelin, as vasopressin, might affect the firing pattern of vasopressin cells
dependent on their ongoing electrical activity so that fast-firing neurones are slowed, and
slow-firing neurones are excited (45).
A direct excitatory effect of apelin on the electrical activity is supported by our in vitro
findings. Apelin-induced inward currents recorded under voltage-clamp suggest the
activation of a non-voltage dependent current and the recorded reversal potential was close
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to the reversal potential of non-selective cation currents of SON neurons, and resembles the
currents obtained with other peptides such as cholecystokinin, angiotensin II, activin A,
neurotensin and PACAP (46-49). However, further investigation is required to determine the
different ion permeability, in other words whether apelin induces an inward calcium current
via a non-specific cationic channel.
The second messenger signalling system utilised by APJ upon binding apelin appears to be
dependent on cell type. In studies using APJ transfected Chinese hamster ovary cells, apelin
inhibits forskolin-induced cAMP production (8;18) suggesting APJ is functionally linked to
Gαi. Apelin can also activate kinases involved in cellular survival such as ERK-1/2 (50;51)
or AKT (52). However, while the neuronal cell lines 293 (8;53) and NT2 (43) respond to
apelin with an increase in [Ca2+]i, APJ expressing Chinese hamster ovary cells do not
(2;50;54). Apelin evoked an increase in [Ca2+]i in vasopressin neurons. Furthermore, apelin
did not increase [Ca2+]i in cells perfused with Ca2+-free solution, indicating that apelin
induces calcium influx, rather than release from intracellular stores. The consequences of
apelin-induced changes in intracellular calcium concentration in magnocellular neurons are
currently unknown.
The local excitatory actions of apelin on the electrical activity of vasopressin neurons may
be mediated through somato/dendritic vasopressin release. Vasopressin neurons discharge in
a characteristic phasic pattern that optimises the efficiency of stimulus-secretion coupling at
the nerve terminals. Magnocellular neurons release large amounts of oxytocin and
vasopressin from their dendrites (55) and dendritically-released vasopressin itself modulates
this phasic activity by a predominantly inhibitory action (32;45). In vivo retrodialysis of
vasopressin onto vasopressin neurons inhibited vasopressin neurons by reducing their firing
rate, whereas, retrodialysis of a V1-receptor antagonist partially reversed the effects of
vasopressin (32). Functional evidence suggests that the effects of vasopressin on electrical
activity are likely to be inhibitory. I.c.v. injection of vasopressin decreases plasma
vasopressin concentration (56), while V1/V2 antagonists enhance peripheral vasopressin
release in response to osmotic stimulation (57).
To assess the effects of apelin on somato/dendritic peptide vasopressin release we used in
vitro release studies from SON explants (35) demonstrating an inhibitory action of apelin on
basal and stimulated somato/dendritic vasopressin release. Our data imply that vasopressin
and apelin are released differentially from vasopressin neurones in which they are co-
localised, but found in neurosecretory granules differing in size and distribution (23). While
the APJ antagonist apelin-13(F13A) blocked the exogenous apelin-13 evoked inward
current, we did not observe an effect of the antagonist on membrane potential or action
potential firing rate, which suggests that apelin is not being tonically released. In addition,
we have not been successful in measuring potassium- stimulated apelin release from our
SON explant preparation, which may be due to the low amount of apelin released and/or the
detection limited of the enzyme immunoassay used (minimum sensitivity: 0.07ng/ml;
Apelin-12 Enzyme ImmunoAssay, Phoenix Pharmaceuticals, Inc. Ca, USA).
It is tempting to speculate that inhibition of dendritic vasopressin release by apelin may
remove an inhibitory tone leading to excitation of vasopressin cell activity. Osmotic
challenges such as dehydration increase both the firing rate of vasopressin cells and
vasopressin release (58;59) and in a dual immuno-labelling confocal microscopy study,
Reaux-Le Goazigo and colleagues (23), have shown that the number and labelling intensity
of magnocellular apelin-immunoreactive cells increased significantly after dehydration,
whereas the number and labelling density of vasopressin-immunoreactive neurons
significantly decreased. The authors speculate that an inhibition of somato/dendritic apelin
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release is partly responsible for the observed effect. However, this hypothesis requires
further evaluation.
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Fig. 1. Immuno-visualisation of APJ in the SON and pituitary
A) Confocal images from hypothalamic and pituitary sections double-labelled with
immunofluorescence antibodies against vasopressin, oxytocin or glial fibrillary acidic
protein (VP, OT and GFAP respectively, red) and the apelin receptor (APJ, green). APJ
immunoreactivity was found in somata/dendrites of vasopressin A, B) and oxytocin neurons
in the SON (D) and axon terminals (C) in the neural lobe of magnocellular neurons.
Immunoreactivity was also seen in the ventral glial lamina of the SON (E). Scale bars in A,
D and E are 100μm and B-C are 10μm.
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Fig. 2. Effects of retrodialysis of apelin on the electrical activity on supraoptic neurons in vivo
Examples of extracellular recordings of the electrical activity of A) vasopressin and C)
oxytocin cells. Apelin-13 was administered by microdialysis administration (retrodialysis)
over 30 min. Phasic vasopressin cells B) show an increase in their activity quotient (n=4)
and continuously active vasopressin cells D) show an overall increase in firing rate (n=4) E)
Oxytocin neurons (n=7) were not significantly affected by the apelin-13 treatment. All
continuously active cells were identified by their response to i.v. CCK showing a decrease in
the firing rate in vasopressin D) and an increase in the firing rate in oxytocin cells C,E).
O.C. optic chiasm, Mean ± S.E.M, *p<0.05.
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Fig. 3. Effects of i.c.v. apelin on the electrical activity on supraoptic vasopressin neurons in vivo
Examples of extracellular recordings of the electrical activity of A) continuous and B)
phasic active vasopressin cells after intracebroventricular (i.c.v.) injection of apelin-13.
Whereas continuous active vasopressin cells C) show no change in firing rate (n=4), phasic
vasopressin cells D) showed a significant increase in their activity quotient (n=4). Mean ±
S.E.M., *p<0.05.
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Fig. 4.
Effects of apelin on vasopressin neurons in vitro: A-D) Examples showing effect of applying
apelin-13 (50 nM) to isolated vasopressin neurons. A) In voltage-clamp mode VP neurons
were held at -70mV and apelin-13 evoked a reversible inward current which lasted at least
as long as apelin-13 was applied. B) Using a ramp protocol described in the inset, the whole
cell current recorded before apelin was applied (i), was subtracted from that recorded after
(ii) and thus the apelin-induced current was derived (iii, grey line). The average apelin-13-
induced current had a reversal potential of -32 ± 2 mV (n=5). C) The apelin-13-induced
current was also shown to be Gd3+ (0.1 mM, n=5) sensitive, suggesting a non-specific
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cation current. D) Apelin-13 did not evoke any current when applied after cells were pre-
treated with 0.1mM apelin-13(F13A) (n=5). E) Apelin-13 evoked a small increase in
[Ca2+]i. in vasopressin neurons (n=12). F) Apelin-13 did not evoke an increase in [Ca2+]i
in the absence of extracellular calcium (n=5).
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Fig. 5.
The effect of applying apelin-13 (50 nM) and the APJ antagonist apelin-13(F13A) (0.1 mM)
on vasopressin neurons in hypothalamic slices. A) Shows an example of apelin-13-induced
increase in action potential firing in a phasic vasopressin neuron. Apelin-13 also depolarised
the neuron (the original membrane potential is indicated by the dotted line, increasing from
-58 to -54 mV). B) An example showing that apelin-13(F13A) had no effect on the
spontaneous action potential firing rate or pattern in a vasopressin neuron. C) The average
firing rate as a percentage of a control period prior to exposure to apelin-13 or
apelin-13(F13A) showed that apelin-13 produced a significant increase in firing rate
(*p<0.05, n=10) while apelin-13(F13A) was without effect (n=10).
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Fig. 6. Effects of apelin on basal peptide release in vitro
Apelin-13 (50 nM) reduced A) basal vasopressin (empty circles/bars), but not oxytocin
release (filled circles/bars) from SON explants with B) no effect of apelin-13 on either
vasopressin or oxytocin release from isolated axon terminals of the neural lobe. Mean ±
S.E.M., n=6, *p<0.05.
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Fig. 7. Effects of apelin on high potassium stimulated peptide release in vitro
Apelin-13 (50 nM) reduced A) high potassium stimulated vasopressin (empty circles/bars),
but not oxytocin release (filled circles/bars) from SON explants with B) no effect of
apelin-13 on either vasopressin or oxytocin release from isolated axon terminals of the
neural lobe. Mean ± S.E.M., n=6, *p<0.05.
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